Kornimate/medical-research-clean huggingface dataset:
gait analyses after resurfacing hip arthroplasty versus metal on metal total hip arthroplasty, an exploratory study

Conditions: Difficulty Walking; Gait, Stumbling

Summary: total hip replacement surgery is a very successful operation with good long-term results. hip resurfacing arthroplasty is offered as a treatment option for young and active patients with osteoarthritis of the hip. it has been proposed as a treatment option for younger patients because of claims that it preserves femoral bone stock and has better functional outcomes. the assessment of gait after hip replacement surgery may be able to determine functional differences between patients who have undergone total hip replacement / arthroplasty (tha) versus hip resurfacing.

a group of 58 patients, part of a ungoing randomized trial comparing resurfacing hip arthroplasty to metal-on-metal total hip arthroplasty, will be invited to a single gait analysis on a trendmill. all patients have reached a follow up of five years. patient 's gait will be assessed during two walking sessions, in both sessions spatio-temporal, kinetic and kinematic parameters will be recorded. * at first when flat walking with increasing speeds to their top walking speed. * secondly: when walking at a fixed speed with an increasing incline to their top walking incline.

Eligibility criteria:
inclusion criteria: * patient part of randomised controlled trial (rct) of hip resurfacing versus mom total hip arthroplasty for symptomatic osteoarthritis of the hip * patient must be able to consent to the study (written informed consent) * patients who are functioning well post-operatively and not under routine follow up * patients who are able to walk without any safety rail assistance on the treadmill exclusion criteria: * patient not originally randomised during an rct of hip resurfacing versus mom total hip arthroplasty * patients who suffer from any neurological or musculoskeletal conditions that might make a gait test dangerous. * patients whose cognitive function prevents them from understanding the study * patients who have had or are awaiting revision surgery for their hip

Keywords: gait disorder resurfacing hip arthroplasty total hip arthroplasty
microwaves ablation of varicose veins

Conditions: Varicose Veins

Summary: lower-limb varicose veins (vvs) are the most common of vascular diseases and affect up to one-third of the population, severely affecting the quality of life (qol) of patients. in past decades, traditional surgical ligation and stripping were the gold standard therapy for patients with vvs; however, traditional methods have demonstrated high complication and recurrence rates. thus, the practices are moving toward minimally invasive alternatives.

lower-limb varicose veins (vvs) are the most common of vascular diseases and affect up to one-third of the population, severely affecting the quality of life (qol) of patients. in past decades, traditional surgical ligation and stripping were the gold standard therapy for patients with vvs; however, traditional methods have demonstrated high complication and recurrence rates. thus, the practices are moving toward minimally invasive alternatives. endo venous thermal ablation, such as radiofrequency ablation and endo venous laser ablation (evla), has become the recommended first-line treatment for vvs worldwide. these endo venous procedures provide a quicker recovery time and improved qol and produce fewer complications than traditional surgery .endo venous microwaves ablation is a minimally invasive procedure in treatment of v.v, investigators confirmed that endo venous microwave ablation (ema) was an effective new technique for the treatment of vvs. on previous trials confirmed that the endo venous microwave ablation procedure demonstrated a shorter procedure time, lower complication, and local recurrence than the endo venous laser ablation procedure. the aim of the study was to determine whether endo venous microwave ablation of varicose vein was associated with better effectiveness and less complications and evaluate the outcome of patients who underwent endo venous microwave ablation (ema).

Eligibility criteria:
inclusion criteria: 1. age between 18 and 60 years, either sex, elective admission 2. primary symptomatic vvs (ceap,c3-c6) 3. recurrent varicose veins after surgery 4. greater saphenous vein diameter up to 3 cm 5. greater saphenous vein with variable depth even with depth less than 6mm 6. greater saphenous vein with tortuosity 7. diabetic patient with risk of wound infection after surgery 8. patient with hostile groin 9. availability of patients for all follow-up visits exclusion criteria: 1. secondary varicose veins 2. acute thrombosis near the saphenous-femoral junction 3. recanalized greater saphenous vein 4. pregnancy
phase ii study of icotinib with concurrent radiotherapy in elderly patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: to investigate the efficacy and toxicity of egfr tyrosine-kinase inhibitor (icotinib) with concurrent radiotherapy in older patients with esophageal cancer.

older patients with esophageal cancer have been correlated with poor prognosis because of having little chance to receive aggressive local therapy, including surgery or concurrent chemoradiotherapy. egfr is overexposed in most of the cases. in this phase ii trial, the efficacy and toxicity of egfr tyrosine-kinase inhibitor (icotinib) with concurrent radiotherapy will be investigated in this setting.

Eligibility criteria:
inclusion criteria: 1. pathologically confirmed esophageal carcinoma 2. stage i～iva by eus and ct/mri, without contraindication for radical radiotherapy 3. aged ≥ 70 and \< 85 years, behavioral status evaluation ecog scores 0-2 4. in 7 days after being screened, subjects should follow the status: wbc ≥ 3.0 x 10\^9/l; anc ≥ 1.5x 10\^9/l; plt ≥ 80 x 10\^9/l; hb ≥ 90 g/l; serum cr ≤ uln; serum bilirubin ≤ 1.5 uln; alt/ast ≤ 1.5 uln 5. subjects should sign for the informed consent 6. subjects should perform good compliance exclusion criteria: 1. patients who have or are currently undergoing additional chemotherapy, radiation therapy or targeted therapy 2. complete obstruction of the esophagus, or patients who have the potential to develop perforation 3. patients with a history of malignancy (except that skin carcinomas or in situ breast cancer, oral cancer and cervical cancer with expected survival ≥2 years 4. patients who have multiple foci esophageal carcinomas 5. patients who are/were given any other medicine tests currently/in last 4 weeks 6. experienced hypersensitiveness with similar medicine or other kinds of bio-medicines 7. patients who have complications as following: (1) uncontrolled angina and heart failure, have a history of hospitalization in 3 months; (2) a history of myocardial infarction in the past 6 months; (3) there is a need for antibiotic treatment of acute bacterial or fungal infection; (4) chronic obstructive pulmonary disease, or other lung disease requiring hospitalization; (5) drug addiction, alcoholism and aids disease or long-term virus carriers; (6) uncontrollable seizures, or loss of insight because of mental illness.

Keywords: radiotherapy icotinib
a study to investigate bio product laboratory ltd (bpl's) factor x in the prophylaxis of bleeding in children <12 years

Conditions: Factor X Deficiency

Summary: the primary objective of the study is to assess the efficacy of factor x in the prevention of bleeding when given as routine prophylaxis over 12 months. the secondary objectives of the study are: 1. to assess the pharmacokinetics of factor x after a single dose of 50 iu/kg. 2. to assess the safety of factor x when given as routine prophylaxis over 6 months (26 weeks).


Eligibility criteria:
inclusion criteria 1. children with hereditary severe or moderate fx deficiency (fx:c \<5 iu/dl), based on their lowest reliable fx:c recorded. 2. children under 12 years old, whose parent/guardian has given informed consent. 3. children with a history of severe bleeding e.g.: intracranial haemorrhage, before starting prophylactic therapy, or a mutation in the f10 gene causing a documented severe bleeding phenotype. exclusion criteria 1. children must not suffer from clinically significant liver disease, renal disease, or other coagulopathy or thrombophilia 2. children must have no history or suspicion of inhibitors to factor x. 3. children who have known or suspected hypersensitivity to the investigational medicinal product or its excipients. 4. children with a history of unreliability or non-cooperation. 5. children who are participating or have taken part in another trial within the last 30 days. 6. children planning more than 4 weeks' continuous absence from the locality of the investigational site, between the screening visit and the end of study visit at approximately 6 months (26 weeks) post-baseline.
primary and secondary hemostasis in elective coronary artery bypass graft surgery

Conditions: Coronary Disease

Summary: patients undergoing elective coronary artery bypass graft surgery (cabg) are treated with platelet inhibitors to reduce myocardial infarction and mortality.however, this can increase perioperative bleeding. a retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective cabg since 5 years. the aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.


Eligibility criteria:
inclusion criteria: * coronary artery bypass graft surgery with or without cardiopulmonary bypass exclusion criteria: * emergency; redo cardiac surgery; combined cardiac surgery; patients with renal insufficiency; patients with acquired coagulation abnormalities
nol index in response to pacemaker stimulation

Conditions: Nociceptive Pain

Summary: the nociception level index (nol index) utilizes various signals to assess the balance of nociception and antinociception during anesthesia. its correlation with nociceptive stimuli and opioids is known, but its response to isolated heart rate changes remains uncertain. the aim is to investigate how cardiac pacing affects the nol index.

the nociception level index (nol index) represents an innovative approach to monitoring nociception during general anesthesia, utilizing a combination of signals from photoplethysmography, accelerometry, thermometry, and skin conductance to assess the balance between nociceptive and antinociceptive states. research has already established how the nol index correlates with both nociceptive stimuli and opioid levels, providing valuable insights into patient responses. however, the impact of changes in heart rate, specifically through isolated cardiac pacing, on the nol index is not yet clear. the primary goal of this study is to explore and understand how cardiac pacing might influence the readings of the nol index, potentially offering a new dimension to managing anesthesia effectively.

Eligibility criteria:
inclusion criteria: * informed consent * preoperative and postoperative sinus rhythm (50-80 bpm) * norepinephrine support \< 100 ng/kg/min exclusion criteria: * redo or emergent surgery * history of any cardiac arrhythmia * any cardiocirculatory support other than norepinephrine * perioperative treatment with beta-blockers, calcium-channel blockers or ivabradine

Keywords: cardiac surgery nociception nol index pacemaker
stretta ,radio frequency ablation (rfa) v/s sham therapy for the treatment of refractory gerd

Conditions: GERD

Summary: gastro-esophageal reflux disease (gerd) is a chronic disorder with significant impact on the quality of life of patients. it may also lead to several complications like peptic strictures, ulcerations, barrett 's disease and subsequently adenocarcinoma of the esophagus. proton pump inhibitors (ppis) are the mainstay of gerd treatment, with up to 90 % of patients with reflux disease becoming asymptomatic while taking ppis. several studies have demonstrated that rf delivery at the gastro-esophageal junction(gej), also called the stretta procedure, induces symptom relief and decreases need of ppi intake in gerd. the investigators propose to perform a sham-controlled randomized study to evaluate the influence of the stretta procedure on symptoms and esophageal acid exposure in patients of refractory gerd.

gastro-esophageal reflux disease (gerd) is a chronic disorder with significant impact on the quality of life of patients. it may also lead to several complications like peptic strictures, ulcerations, barrett 's disease and subsequently adenocarcinoma of the esophagus. proton pump inhibitors (ppis) are the mainstay of gerd treatment, with up to 90 % of patients with reflux disease becoming asymptomatic while taking ppis. however, the treatment of patients with proven gerd, who have an unsatisfactory response to high doses of ppis remains a challenge. a number of endoscopic procedures, aimed at improvement of the barrier function of the lower esophageal sphincter (les), have emerged over the last decade. several studies have demonstrated that rf delivery at the gastro-esophageal junction(gej), also called the stretta procedure, induces symptom relief and decreases need of ppi intake in gerd. the investigators propose to perform a sham-controlled randomized study to evaluate the influence of the stretta procedure on symptoms and esophageal acid exposure in patients of refractory gerd.

Eligibility criteria:
inclusion criteria: * age \> 18years * small hiatus hernia (\< 2-3 cm) * los angeles grade 'a' or 'b' reflux esophagitis * les pressure : 5 - 15 mm hg * ppi dependent / refractory gerd * 24 hr acid exposure study showing abnormal esophageal acid exposure \> 4% * demeester score \>14.7 * esophageal manometry showing normal peristalsis exclusion criteria * age \< 18 years * large hiatus hernia (\> 3 cm) * los angeles grade 'c' or 'd' reflux esophagitis * les pressure : \ 15 mm hg * underlying coagulation disorder * previous esophageal or gastric surgery * h/o coronary artery disease (cad) * esophageal manometry showing ineffective peristalsis
1 year study trav/brinz qd fixed combination versus cosopt

Conditions: Glaucoma; Ocular Hypertension

Summary: parallel, multi-center, double-masked, active controlled, three arm study comparing the iop lowering efficacy and safety over 12 months of morning or evening instillations of travoprost/brinzolamide vs. cosopt dosed in the morning and evening in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * iop at screening visit \<18mmhg in at least one eye mean iop in same eye (at both eligibility 1 \&2 visits) * 24 and ≤ 36 mmhg at 9:00 * 21 and ≤ 36 mmhg at 11:00 and 16:00 exclusion criteria: * severe central visual field loss angle shaffer grade \ 0.8 (horizontal or vertical measurement)

Keywords: glaucoma patients with open-angle glaucoma or ocular hypertension
magnesium administration in liver transplantation and reperfusion injury

Conditions: Living Donor Liver Transplantation; Reperfusion Injury

Summary: the purpose of this study is to evaluate the effect of intravenous magnesium infusion before reperfusion with employing some clinical parameters including blood lactate levels, because the intraoperative changes in the blood lactate levels after hepatic allograft reperfusion served as an accurate predictor of the initial graft function in living donor liver transplantation.

clinically significant hemodynamic deterioration occurs immediately after reperfusion of the grafted liver by unclamping of the portal vein. profound hypotension, bradycardia, systemic vasodilation, and a decrease in cardiac output have been reported, and this is described as postreperfusion syndrome (prs). this hemodynamic instability usually requires adequate and aggressive cardiovascular pharmacologic management and fluid support, and recovers slowly over a period of 30 to 60 minutes.because the severity of prs correlates with patient and allograft outcome, prevention of its occurrence or attenuation of the hemodynamic changes may improve outcome. however, not much is known about how to protect against this reperfusion injury. reperfusion injury also occurs in myocardial infarction, ischemic spinal cord injury and stroke. recent experiments have shown protective effects of magnesium to reduce the reperfusion injury of these conditions. magnesium administration may provide cellular protection during ischemia and reperfusion with stabilizing the cellular transmembrane potential, suppressing excessive cellular calcium influx and energy demand.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective living donor liver transplantation exclusion criteria: * pediatric patients * re-transplantation * renal dysfunction * cardiovascular disease

Keywords: magnesium and reperfusion injury
stereotactic body radiotherapy for the treatment of opd

Conditions: NSCLC

Summary: halt is a phase ii, randomised multi-centre study with integrated seamless continuation to phase iii trial following acceptable safety and feasibility assessment. halt aims to recruit 110 patients with mutation positive advanced nsclc with oligoprogressive disease (opd) following initial response to a tyrosine kinase inhibitor (tki).

eligible patients will be randomised to receive either sbrt or no sbrt at a ratio of 2:1 (sbrt : no sbrt), with all patients continuing to receive background treatment with tki therapy as clinically indicated and as per standard care. patients randomised to receive sbrt will receive a dose and fractionation schedule dependent on opd lesion site and proximity to critical normal tissues. all patients will be seen 8 weeks post randomisation, then 3 monthly in line with routine care. halt aims to assess whether in patients with mutation positive advanced nsclc the use of sbrt to ≤ 3 sites of opd with continuation of tki improves progression-free survival (pfs) compared with continuation of tki alone.

Eligibility criteria:
inclusion criteria: 1. male or female, ≥ 16 years of age 2. established histological diagnosis of advanced nsclc, not suitable for radical treatment, with defined actionable mutation receiving targeted tki therapy 3. clinical and/or radiologically confirmed response to tki therapy (assessed locally usually 2-3 months post commencing tki) 4. confirmed opd defined as ≤ 5 extracranial sites of progressive disease. all sites must be visible, imaging defined targets and suitable for treatment with sbrt as determined by the virtual multi-disciplinary team (mdt) and in accordance with the halt radiotherapy planning and delivery guidance document. 5. adequate baseline organ function to allow sbrt to all relevant targets 6. predicted life expectancy ≥ 6 months 7. karnofsky index ≥ 60% and ecog 0-2 8. provision of written informed consent exclusion criteria: 1. \> 5 extracranial sites of progressive disease 2. progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or srs. previously treated brain metastases (i.e palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for ≥ 6 months are permissible. 3. prior radiotherapy near the oligoprogressive lesion precluding ablative sbrt. suitability of lesions for ablative sbrt as part of the trial defined in section 4.1 of this document and will be determined by the halt virtual mdt 4. co-morbidities considered clinically precluding the safe use of sbrt (as detailed in the halt radiotherapy planning and delivery guidelines). 5. any psychological, sociological or geographical issue potentially hampering compliance with the study 6. pregnancy

Keywords: sbrt oligoprogressive disease nsclc tki
clinical efficacy of indomethacin in early treatment of acute pancreatitis

Conditions: Acute Pancreatitis; Systemic Inflammatory Response Syndrome

Summary: acute pancreatitis is a common critical disease of the digestive system. accumulated data showed that overexpression of cyclooxygenase-2 (cox-2) in acute pancreatitis and experimental pancreatitis could be attenuated with cox-2 inhibitors. in recent years, it has been found that timely administration of indomethacin or diclofenac sodium to anus after ercp can significantly reduce the incidence of ap after ercp in patients at high risk of ap. the aim of this study was to evaluate the efficacy of rectal indomethacin in reducing the systemic inflammatory response syndrome (sirs) score in ap patients.


Eligibility criteria:
inclusion criteria: (i) either gender aged 18-70 years; (ii) a confirmed diagnosis of ap; (iii) the time interval from the onset of symptoms to admission was no more than 48 h; (iv) written informed consent was obtained from the patients or their legal representatives. exclusion criteria: (i) pregnancy and breast feeding mother; (ii) severe chronic diseases such as cardiac dysfunction, chronic obstructive pulmonary disease, renal insufficiency, cirrhosis, inflammatory bowel diseases, and malignancies; (iii) peptic ulcer; (iv) pancreatitis due to trauma; (v) drug allergy; (vi) drug abuse and psychosis.

Keywords: non-steroidal anti-inflammatory drugs indomethacin
dry needling with percutaneous electrical nerve stimulation and exercises for non-specific chronic neck pain

Conditions: Neck Pain

Summary: the aim of this study is to compare the effects of applying dry needling with percutaneous electrical nerve stimulation + exercises verus therapeutic execises in patients with non-specific chronic neck pain.

globally, neck pain is considered the fourth leading cause of years lived with disability. it is estimated that up to 70% of the world's population will experience neck pain at least once in their lifetime, and between 50% and 85% of cases will become chronic within a five-year period. the point prevalence of neck pain in the adult population, aged 15-74 years, ranges from 5.9% to 38.7%. this prevalence has been observed to peak in the 50-74 age group. in 2017, the global age-standardized prevalence and incidence of neck pain were 3551.1 and 806.6 per 100,000 population, respectively. dry needling with percutaneous electrical nerve stimulation has positive short-term effects on pain intensity, pain-related disability, and mood in patients with chronic nonspecific neck pain, compared with no or minimal intervention. however, the long-term impact could not be assessed due to a lack of available studies. furthermore, strong evidence has been found suggesting that dry needling with percutaneous electrical nerve stimulation may improve mental well-being and mood in patients with chronic neck pain, especially in those with pain induced by high levels of stress.

Eligibility criteria:
inclusion criteria: * men and women aged between 30 and 65 years. * a diagnosis of non-specific neck pain, * acceptance and signing of informed consent for voluntary participation in the research study. * not currently receiving physiotherapy. exclusion criteria: * patients undergoing rehabilitative treatment for cervical pathologies. * patients with osteosynthesis material at the cervical level and/or cardiac, epileptic, or tumour-related complications. * patients who have undergone radiotherapy. in the last 6 months.

Keywords: exercise quality of life electrical stimulation pain